LixisenatideGLP-1 receptor agonist medicine
Lixisenatide was developed for type 2 diabetes, with particular relevance to meal-related glucose. Its clinical history needs to be separated from the current availability of individual branded products.
What is Lixisenatide?
Lixisenatide is a GLP-1 receptor agonist developed for type 2 diabetes, particularly meal-related glucose control. EMA records withdrawal of the standalone EU product Lyxumia in December 2025 for commercial reasons. 1 2
How it works
It activates GLP-1 receptors and affects insulin secretion, glucagon and gastric emptying, with meal-related glucose an important part of its clinical profile. 2
Effects studied
Glucose and cardiovascular outcomes
Diabetes studies examine glucose control. ELIXA examined cardiovascular outcomes in a defined high-risk population; cardiovascular safety and cardiovascular benefit are separate questions.
Evidence: Diabetes product information and cardiovascular outcomes trial. 2 3
What does the evidence show?
Diabetes and cardiovascular trial history; EMA withdrawal checked
A meal-related mechanism
Lixisenatide activates the GLP-1 receptor, influencing insulin secretion, glucagon and gastric emptying. Its pharmacological profile made control of glucose around meals an important part of its clinical use. Describing that use as general metabolic enhancement would overstate its scope.
What the clinical evidence asks
Diabetes studies examine glucose control, while the retained ELIXA reference concerns cardiovascular outcomes in a defined high-risk population. Demonstrating that a treatment does not increase cardiovascular events is different from demonstrating that it reduces them. The wording of the endpoint matters.
A change in European availability
The EMA states that Lyxumia’s marketing authorisation was withdrawn in December 2025 at the manufacturer’s request for commercial reasons. The decision should not be attributed to new safety problems. Presenting only the historical EU approval would also leave out this change in availability. 1
Keep combination products separate
A medicine containing lixisenatide together with insulin has its own formulation, indication and safety instructions. It should not inherit a blanket availability statement from Lyxumia, or vice versa. Gastrointestinal effects and hypoglycaemia considerations also depend on the accompanying treatment. The useful next step is checking the exact product and country rather than relying only on the active ingredient’s name.
Safety & status
Gastrointestinal effects and hypoglycaemia considerations depend on the accompanying treatment. Products combining lixisenatide with insulin have separate instructions and safety context. 2
Country and product status
EMA records withdrawal of Lyxumia’s EU authorisation on 18 December 2025 for commercial reasons. This statement concerns that product, not every combination containing lixisenatide.
Frequently asked questions
Was Lyxumia withdrawn because of a new safety problem?
EMA describes a manufacturer-requested withdrawal for commercial reasons, not a newly identified safety reason. 1
Does that withdrawal apply to every lixisenatide product?
No. A combination containing insulin is a separate product and needs its own availability check. 1
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- EMA · Lyxumia overview and withdrawal European regulator · Regulator information checked 27 October 2026; indication-specific, not a review of all jurisdictions.
- Lixisenatide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Lixisenatide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.